

Curriculum Vitae: Professor NADIA HARBECK, MD PhD

CURRENT STATUS:

Director, Breast Center, University of Munich (LMU), Germany (since 12/2011).
 Head, Oncological Therapy & Clinical Trials Unit, Dept. OB&GYN, LMU (since 12/2011).
 Full Professor, Chair for Conservative Oncology (Dept. OB&GYN), LMU (since 12/2011).
 Chair, Center for Hereditary Breast and Ovarian Cancer, LMU (since 2019).
 Steering Committee Member, Comprehensive Cancer Center LMU (CCC^{LMU}) (since 2012).
 Member, Clinical Trial Sponsorship Commission, LMU University Hospital (since 2020).
 Member, Research Commission, LMU Medical Faculty (since 2022).
 ESMO Director of Education (2023-2025), ESMO Executive Board Member

PREVIOUS POSITIONS:

Member Ethics Committee (IRB), Medical Faculty, LMU (2016-2022).
 Executive Board Member, Munich Comprehensive Cancer Center, CCC^{Munich} (2014-2018).
 Head: Breast Center, Oncological Therapy and Clinical Trials Unit, Dept. OB&GYN, Cologne University, Germany (03/09-11/11).
 Steering Committee Member, Center for Integrated Oncology, Cologne/Bonn (03/09-11/11).
 Steering Committee Member, Clinical Trials Center, University of Cologne (12/09-11/11).
 Member Ethics Committee (IRB), Medical Faculty, University of Cologne (12/09-11/11).
 Head (*Leitende Oberärztin*): Conservative Senology, Dept. OB&GYN, TUM (2005-2009).
 Consultant (*Oberärztin*), Dept. OB&GYN, TUM (2000-2004).
 Specialist (*Fachärztin*), Dept. OB&GYN, TUM (1998-99).
 Resident (*Assistenzärztin*), Dept. OB&GYN, TUM (1992-98).
 Intern (*Ärztin im Praktikum*), Dept. OB&GYN, TUM (1990-91).

EDUCATION AND PROFESSIONAL DEGREES:

Board certification (*Zusatzbezeichnung*) for Genetic Counseling OB&GYN (*fachgebundene genetische Beratung*) (31-01-2019).
 Training Permit (*Weiterbildungsberechtigung*) "Medical Tumor Therapy", LMU (since 2019).
 Training Permit (*Weiterbildungsberechtigung*) "Medical Tumor Therapy", Cologne (2010-11).
 Board certification (*Zusatzbezeichnung*) for "Medical Tumor Therapy" (13-07-2009).
 Head of Conservative Senology, TUM (1-1-2005 until 28-02-2009).
 Associate Professor for OB&GYN, Technical University of Munich, Germany (TUM) (8-12-03).
 Research Group leader „Tumor invasion and Metastasis“, TUM (1999-2002).
 Consultant (*Oberarzt*) for Obstetrics and Gynecology, TUM (1-1-2000).
 M.D., Ph.D (*Habilitation, Dr. med. habil., Privatdozent*), TUM (12-28-1998).
 Specialist for Obstetrics and Gynecology. German National Board certification (9-15-1998).
 M.D. (*Dr. med.*), Ludwig-Maximilians-University, Munich, Germany (7-1-93).
 German National Board certification as physician (*Approbation*) (2-4-92).
 Medical School, Ludwig-Maximilians-University, Munich, Germany (1983-89).
 Photography Training, Welland and St. Catharines, Ontario, Canada (1981-82).
 High School *Willi-Graf Gymnasium*, Munich, Germany (1972-81) (valedictorian).
 Elementary School *Am Bayernplatz*, Munich, Germany (1968-72).

SPECIAL CLINICAL INTERESTS: Breast Cancer and Gynecological Oncology.

CLINICAL TRIAL EXPERTISE in breast cancer:

Principal Investigator (PI, LKP) or Steering committee member: numerous national and international Phase I-III therapy trials and translational research studies.
 Data Monitoring Committee: Several national and international therapy trials.
 Co-Director of West German Study Group (WSG, BIG Member) (since 2009).
 Founding and Steering Committee member, AGO-B Study Group (BIG member) (since 2009).

Member BIG / NABCG Joint Leadership Committee (2007-11). Member TransBIG (until 2010). Co-Chair TransALTTO; Member TransHERA; Subboard member (adjuvant, metastatic, translational) German Breast Group (GBG) (2006-10). Head, Clinical Trials Unit, Dept. OB&GYN, University of Munich, Germany (since 12/2011). Head, Clinical Trials Unit, Dept. OB&GYN, University of Cologne, Germany (2009-2011). Head, Clinical Trials Unit, Dept. OB&GYN, Technical University, Munich, Germany (2001-09). Clinical Research Training: Fachkunde Strahlenschutz (30.01.21); Investigator Training: GCP-Update 2.7.25; ICH-GCP (AMG) Update 31.01.2022; AMG Prüfer Aufbaukurs 16.11.2018; Prüfarztkurs 07. /14.04.16; Medicinal Product Law: ICH/GCP (AMG, MPDG) Update (22.11.23); ICH/GCP-MPDG Update 04.02.2022; MPG Aufbaukurs Prüfleiter 20.09.2019; MPG Grundlagenkurs 13.06.2018.

MD (Dr.med.) – THESIS:

“Detection of tumor cells in the bone marrow of breast cancer patients at time of primary therapy: prognostic and clinical relevance - results of a 5 year follow-up.” (*Br J Cancer 1994*). Advisor: Prof. W. Eiermann, MD; Ludwig-Maximilians-University (LMU), Munich, Germany.

MD-PhD (Dr. med. habil) THESIS:

„Clinical relevance of proliferation and invasion factors in breast cancer.“ Dept. OB&GYN (Head: Prof. H. Graeff), Technical University, Munich, Germany (*BCRT 1999; Br J Cancer 1999*).

HONORS & AWARDS:

Bavarian Order of Merit (*Bayerischer Verdienstorden*) 09-07-2025

Adjunct Professor, Medical University of Vienna, Austria (since 2024)

German Cancer Award (Deutscher Krebspreis) for Clinical Research (2023)

Highly Cited Researcher 2021-2024

UPO Alumni Award for Women in Academy and Research (2021)

„Best Abstract“, German Society of Senology (2021).

ESMO Lifetime Achievement Award (2020)

Keynote Speaker, Women for Women, Rome (2019)

Keynote Speaker, European Breast Cancer Conference EBCC11, Barcelona (2018)

Keynote Speaker, PragueONCO, Prague (2017)

Patient Award, Bavarian Cancer Society (2015)

Panel/Faculty Member: St. Gallen Consensus on Primary Breast Cancer, Vienna (since 2015)

Medicine Management Award (2015)

Keynote Speaker, Asian Pacific Breast Cancer Symposium (APBCS), Brisbane (2015)

Keynote Speaker, Russian Society Clinical Oncology (RUSSCO), Moskau (2015)

Claudia von Schilling Award, MHH Hannover, Germany (2012)

Panel/Faculty Member: Advanced Breast Cancer Consensus (ABC), Lisbon (since 2011).

Panel/Faculty Member: Breast Cancer in Young Women Conference (BCY) (since 2012).

Keynote Speaker, Danish Cancer Society, Copenhagen (2010).

Opening Lecture (in memory of Lale Atahan), IBCM-2, Sarajevo (2009).

Emmanuel van der Schueren Invited Lecture (*EBCC Award*), EBCC 6, Berlin (2008).

Keynote lecture “Breast Cancer”, German Cancer Congress, Berlin (2008).

“Innovators in Breast Cancer” (Chair: G. Hortobagyi, Houston, USA) (2002-2004).

Schmidt Matthiesen Award for Gynecological Oncology (2002).

Preceptorship (R. Ozols, MD), Fox Chase Cancer Center, Philadelphia, USA (2002).

AstraZeneca Scholar Award, 24th San Antonio Breast Cancer Symposium (2001).

ASCO Fellowship Merit Award for the highest ranking abstract (2001).

AACR Scholar-In-Training Award for Promising Clinical or Translational Research (2001).

„Best Abstract“, German Society of Senology (1997).

Young Investigators Award of the Clinical Cytometry Society, USA (1995).

Research Fellowship, Technische Universität München (1994 - 95).

Scientific Award of the Bavarian Society of Obstetrics & Gynecology (1994).

Fellowship of the European School of Oncology (1993).

Bavarian Merit Scholarship for highly gifted students (1983-1989).

PUBLICATIONS:

718 original publications (*PUBMED*); in addition books, book chapters etc. IF_{cumulative} > 7,000
h-index 100

PATENTS: 9 patent applications filed / patents granted (since 1999)

EDITORIAL BOARDS:

Editor-in-chief (EIC): Breast Care (Founding EIC)

Associate Editor: Therapeutic Advances in Medical Oncology (since 2018)

Editorial Board Member: Future Oncology; Gene Therapy and Molecular Biology / Cancer Therapy; Journal of Clin. Oncology; Journal Onkologie; Molecular Oncology; Onkologie heute. Scientific reports (Nature Publishers).

MEMBERSHIP and RESPONSIBILITIES IN CLINICAL ORGANIZATIONS:

Founder: GEMKOM (2014) - scientific provider for CANKADO ehealth (www.cankado.com)

Executive Committee/Board of Directors: ESMO EC: Director of Education (2023-2025); EORTC EC: Chair, Translational Research Division (2009-2015); EORTC Receptor and Biomarker Group (2002-2005).

Steering committee member: AGO Annual Breast Cancer Guidelines (DGGG, DKG) (since 2001). *European Organisation for Medical Oncology (ESMO)* Section Chair Breast Cancer Guidelines (since 2020). German Interdisciplinary S3 Breast Cancer Guidelines (since 2012). AGO TRAFO “Translational Research” Commission (DGGG, DKG) (2004-2010). DGGG Research Commission (2008-2010). EORTC Pathobiology Group (PBG, 2006-2015). Project Group “Breast Cancer” Tumorcenter Munich (2005-2009; 2014-2022).

Memberships: several national and international professional and scientific organizations

RESPONSIBILITIES IN SCIENTIFIC ORGANIZATIONS: ESMO Subject Editor Breast Cancer Guidelines (since 2022); ESMO Breast Cancer Faculty (since 2022); ASCO Annual Meeting Educational Committee (2022-2025); Deutsche Krebshilfe (German Cancer Aid) Member Translational Research Commission (2009-18). Brustkrebs Deutschland, Beirat (seit 2009)

SCIENTIFIC CONFERENCE (Co-)CHAIR: COMBAT (Founding Chair, annually 2008-2017); Patientinnentag Köln (Founding Chair, annually 2009-2011); Kölner Brustkrebssymposium (Founding Chair, annually 2009-2011); ENASCO Tutorial 2010 (Hollywood, FL, USA); IMPAKT 2011 (Brussels); ENASCO 2011 (Brussels); Mildred Scheel Cancer Conference (bi-annually 2013-2019, Bonn); Gipfelstürmer (annually 2013-2019, 2024-2025 München); Patientinnentag München (annually since 2013); Münchner Symposium/Wintersymposium (annually since 2013); EBCC 10, Track Chair Systemic Therapy (Amsterdam) 2016; ESMO 2017, Track Chair early breast cancer (Madrid); ESMO 2017, Track Chair early breast cancer (Madrid); Director-elect (2017-2018) and ESMO Course Director (2019-2024) Methods in Clinical Cancer Research Workshop MCCR (ECCO-AACR-EORTC-ESMO); Co-Chair, ENDEAVOUR Program (since 2018); Chair European Breast Cancer Conference, EBCC12 (2020). Co-Chair: ESMO Summit Africa 2024-2025, ESMO Summit Latin America 2024-2025; Educational Chair: ESMO 2025: ESMO Asia 2024-2025.

SCIENTIFIC CONFERENCE EXECUTIVE, ORGANIZING or STEERING COMMITTEE MEMBER: several national and international congresses, such as EBCC11 2018, SC Advanced Disease (Barcelona); ESMO 2018: SC Metastatic Breast Cancer; Executive

Committee EBCC 13 (2022). ESMO 2023: SC Metastatic Breast Cancer. ESMO 2024, SC Early Breast Cancer.

REVIEWER (JOURNALS): numerous (inter-)national journals

REVIEWER (JURY Member, GRANTS): *AACR Princess Takamatsu Memorial Lectureship Committee* (2025); *AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research Award Committee* (2024); *AIRC Foundation for Cancer Research* (2023-24); *Sharing Progress in Cancer Care (SPCC)* (2022-24); *Fonds de la Recherche Scientifique FNRS*, Belgien (2015); *CREATE* (Lund University 2013-15); *Institut National du Cancer INCA* (France) (2011-15); *K.G. Jebsen Foundation*, Norwegen (2011); *Swedish Research Council Medicine and Health* (2010); *National Spr/SR Academic Fellowship Programme Committee* (Ireland) (2009); *Fondation Fournier-Majoie pour l'Innovation* (Belgium), Jury (2007-09).

OTHERS: Born in Munich, married, four children; German citizen.
Languages (native fluency): German, English.

OFFICE: Breast Center, Dept. OB&GYN, LMU University Hospital, Marchioninistr. 15, 81377 Munich, Germany. Tel.:+49-89-4400-77581 (Fax: -77582).
nadia.harbeck@med.uni-muenchen.de